Prostacyclin is a fundamental signaling pathway traditionally associated with the cardiovascular system and protection against thrombosis but which also has regulatory functions in fibrosis, proliferation, and immunity. Prevailing dogma states that prostacyclin is principally derived from vascular endothelium, although it is known that other cells can also synthesize it. However, the role of nonendothelial sources in prostacyclin production has not been systematically evaluated resulting in an underappreciation of their importance relative to better characterized endothelial sources..
Prostacyclin (PGI2) is a member of the prostaglandin family of bioactive lipids. Its best-characteri...
AbstractProstacyclin is generated by cultured rat endothelial cells. Compound blocking activity of p...
Endothelial cells can release substances which profoundly affect vascular tone and platelet function...
Prostacyclin is a short-lived metabolite of arachidonic acid that is produced by several cells in th...
We examined the effect of highly purified platelet-derived growth factor (PDGF) on prostacyclin (PGI...
Statins have become a cornerstone of risk modification for ischaemic heart disease patients. A numbe...
Aims: The mobilization of endothelial progenitor cells (EPC) and their functioning in postnatal neov...
Rationale: Endothelial cells and platelets, which respectively produce anti-thrombotic prostacyclin ...
A growing body of evidence outlines the key roles ofcirculating endothelial progenitor cells (EPCs) ...
Date of Acceptance: 11/12/2014 This is an open access article distributed under the terms of the Cre...
The cardioprotective hormone prostacyclin is a potent inhibitor of platelet activation and is produc...
OBJECTIVE: Until recently, prostacyclin (PGI2) biological activities were thought to be exclusively ...
Atherosclerosis and restenosis are proliferative vascular diseases involving, in part, deregulated v...
The following chapter addresses vascular fibroblasts in a healthy, quiescent state, as well during v...
Pulmonary arterial hypertension (PAH) is a progressive vascular remodelling disease where patients u...
Prostacyclin (PGI2) is a member of the prostaglandin family of bioactive lipids. Its best-characteri...
AbstractProstacyclin is generated by cultured rat endothelial cells. Compound blocking activity of p...
Endothelial cells can release substances which profoundly affect vascular tone and platelet function...
Prostacyclin is a short-lived metabolite of arachidonic acid that is produced by several cells in th...
We examined the effect of highly purified platelet-derived growth factor (PDGF) on prostacyclin (PGI...
Statins have become a cornerstone of risk modification for ischaemic heart disease patients. A numbe...
Aims: The mobilization of endothelial progenitor cells (EPC) and their functioning in postnatal neov...
Rationale: Endothelial cells and platelets, which respectively produce anti-thrombotic prostacyclin ...
A growing body of evidence outlines the key roles ofcirculating endothelial progenitor cells (EPCs) ...
Date of Acceptance: 11/12/2014 This is an open access article distributed under the terms of the Cre...
The cardioprotective hormone prostacyclin is a potent inhibitor of platelet activation and is produc...
OBJECTIVE: Until recently, prostacyclin (PGI2) biological activities were thought to be exclusively ...
Atherosclerosis and restenosis are proliferative vascular diseases involving, in part, deregulated v...
The following chapter addresses vascular fibroblasts in a healthy, quiescent state, as well during v...
Pulmonary arterial hypertension (PAH) is a progressive vascular remodelling disease where patients u...
Prostacyclin (PGI2) is a member of the prostaglandin family of bioactive lipids. Its best-characteri...
AbstractProstacyclin is generated by cultured rat endothelial cells. Compound blocking activity of p...
Endothelial cells can release substances which profoundly affect vascular tone and platelet function...